Saretpa

FDA finally responds to demand for Duchenne Muscular Dystrophy guidance
BioPharma Dive
Wed, 06/10/15 - 10:58 am
FDA
Duchenne Muscular Dystrophy
Saretpa
PTC Therapeutics
Pfizer
Biomarin